Thrombotic thrombocytopenic purpura: Recognition and management

International Journal of Hematology

Volumn 91, Issue 1, 2010, Pages 36-45

  Kiss, Joseph E ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR TRANSFUSION MEDICINE   (United States)

Author keywords

ADAMTS13; Plasma exchange; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CD20 ANTIBODY; CLOPIDOGREL; COLLAGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPYRIDAMOLE; FRESH FROZEN PLASMA; GEMCITABINE; IMMUNOGLOBULIN; MITOMYCIN C; PENTOSTATIN; RITUXIMAB; SHIGA TOXIN; TACROLIMUS; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; DIGESTIVE SYSTEM CANCER; ENDOTHELIUM CELL; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELLP SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; MICROANGIOPATHY; MORTALITY; MULTIPLE ORGAN FAILURE; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PLASMAPHERESIS; PREGNANCY; PROGNOSIS; PROTEIN TARGETING; PUERPERIUM; REVIEW; SPLENECTOMY; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

ADAM PROTEINS; AUTOANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 75049083683     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0478-z     Document Type: Review

References (72)

1. SK Vesely JN George B Lammle JD Studt L Alberio MA El-Harake, et al. 2003 ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood 102 1 60 68 10.1182/blood-2003-01-0193 1:CAS:528:DC%2BD3sXltFemtLY%3D 12637323 (Pubitemid 36759636)
2. JN George DR Terrell KK Swisher SK Vesely 2008 Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry J Clin Apher 23 129 137 10.1002/jca.20169 18618590
3. P Coppo A Veyradier 2009 Thrombotic microangiopathies: towards a pathophysiology-based classification Cardiovasc Haematol Disord Drug Targ 9 36 50 10.2174/187152909787581318 1:CAS:528:DC%2BD1MXks1Cgtb0%3D
4. M Scully H Yarranton R Liesner J Cavenagh B Hunt S Benjamin, et al. 2008 Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features Br J Haem 142 819 826 10.1111/j.1365-2141.2008.07276.x
5. M Matsumoto H Yagi H Ishizashi H Wada Y Fujimura H Wada Y Fujimura 2004 The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Semin Hematol 41 1 68 74 10.1053/j.seminhematol.2003.10.009 14727261 (Pubitemid 38057787)
6. G Antoine K Zimmermann B Plaimauer M Grillowitzer J Studt B Lämmle, et al. 2003 ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13 Br J Haem 120 821 824 10.1046/j.1365-2141.2003.04183.x 1:CAS:528:DC%2BD3sXjtVeqsrs%3D (Pubitemid 36315105)
7. F Scheiflinger P Knöbl B Trattner B Plaimauer G Mohr M Dockal, et al. 2003 Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS13) in a patient with thrombotic thrombocytopenic purpura Blood 102 3241 3243 10.1182/blood-2003-05-1616 1:CAS:528:DC%2BD3sXosleku7s%3D 12855569 (Pubitemid 37314762)
8. M Rieger PM Mannucci JAK Hovinga A Herzog G Gerstenbauer C Konetschny, et al. 2005 ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases Blood 106 1262 1267 10.1182/blood-2004-11-4490 1:CAS:528:DC%2BD2MXosVejtrw%3D 15890682 (Pubitemid 41129589)
9. HM Tsai 2003 Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura J Am Soc Nephrol 14 4 1072 1081 10.1097/01.ASN.0000060805.04118.4C 12660343 (Pubitemid 36359290)
10. CA Karpac X Li DR Terrell JA Kremer Hovinga B Lämmle SK Vesely, et al. 2008 Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison Br J Haem 141 696 707 10.1111/j.1365-2141.2008.07116.x (Pubitemid 351667636)
11. S Allford BJ Hunt P Rose SJ Machinet On Behalf of the Haemostasis and Thrombosis Task Force of the British Committee For Standards In Hematology 2003 Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anemias Br J Haem 120 556 573 10.1046/j.1365-2141.2003.04049.x
12. AMS Melnyk K Solez CM Kjellstrand 1995 Adult hemolytic-uremic syndrome Arch Intern Med 155 2077 2084 10.1001/archinte.155.19.2077 1:STN:280: DyaK28%2FhtFGltA%3D%3D 7575067
13. A Zakarija C Bennett 2005 Drug-induced thrombotic microangiopathy Semin Thromb Hemost 31 6 681 690 10.1055/s-2005-925474 1:CAS:528: DC%2BD28XptlSgug%3D%3D 16388419 (Pubitemid 43063086)
14. CL Bennett B Kim A Zakarija N Bandarenko DK Pandey CG Buffie SERF-TTP Research Group, et al. 2007 Two mechanistic pathways for thienopyridine- associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project J Am Coll Cardiol 50 1138 1143 10.1016/j.jacc.2007.04.093 1:CAS:528:DC%2BD2sXhtVCmu7bP 17868804 (Pubitemid 47381493)
15. K Kojouri SK Vesely JN George 2001 Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes Ann Intern Med 135 1047 1051 1:STN:280:DC%2BD38%2FivFWiug%3D%3D 11747383
16. YA Park SN Hay KE King K Matevosyan J Poisson A Powers, et al. 2009 Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy J Clin Apher 24 3 115 119 10.1002/jca.20194 19260037
17. T Uchida H Wada M Mizutani M Iwashita H Ishihara T Shibano Research Project on Genetics of Thrombosis, et al. 2004 Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura Blood 104 2081 2083 10.1182/blood-2004-02-0715 1:CAS:528: DC%2BD2cXotVOqurw%3D 15126318 (Pubitemid 39297860)
18. S Becker G Fusco J Fusco R Balu S Gangjee C Brennan Collaborations in HIV Outcomes Research/US Cohort, et al. 2004 HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study Clin Infect Dis 39 Suppl 5 S267 275 10.1086/422363 15494898 (Pubitemid 39447302)
19. AC Gruszecki G Wehrli BD Ragland VVB Reddy L Nabell A Garcia-Hernandez, et al. 2002 Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura Am J Hematol 69 228 231 10.1002/ajh.10063 11891814 (Pubitemid 34177481)
20. N Novitsky J Thomson L Abraham C du Toit A McDonald 2005 TTP in patients with retroviral infection is highly responsive to plasma infusion therapy Br J Haematol 128 373 379 10.1111/j.1365-2141.2004.05325.x (Pubitemid 40216160)
21. KK Francis N Kalyanam DR Terrell SK Vesely 2007 Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases Oncologist 12 11 19 10.1634/ theoncologist.12-1-11 17227897 (Pubitemid 46143499)
22. L Oberic M Buffet M Schwarzinger A Veyradier K Clabault S Malot, et al. 2009 Cancer awareness in atypical thrombotic microangiopathies Oncologist 14 769 779 10.1634/theoncologist.2009-0067 19684072
23. L Qu JE Kiss 2005 Thrombotic microangiopathy in transplantation and malignancy Semin Thromb Hemost 31 691 699 10.1055/s-2005-925475 16388420 (Pubitemid 43063087)
24. VT Ho C Cutler S Carter P Martin R Adams M Horowitz, et al. 2005 Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation Biol Blood Marrow Transplant 11 571 575 10.1016/j.bbmt.2005.06. 001 16041306 (Pubitemid 41001631)
25. JE Sadler 2008 Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura Blood 112 11 18 10.1182/blood-2008-02-078170 1:CAS:528:DC%2BD1cXotlymu7o%3D 18574040
26. Mannucci PM, Peyvandi F. TTP and ADAMTS13: when is testing appropriate? Hematology. 2007;121-6.
27. XL Zheng RM Kaufman LT Goodnough JE Sadler 2004 Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura Blood 103 11 4043 4049 10.1182/blood-2003-11-4035 1:CAS:528:DC%2BD2cXkvVyisbs%3D 14982878 (Pubitemid 38685342)
28. Y Mori H Wada EC Gabazza N Minami T Nobori H Shiku, et al. 2002 Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity Transfusion 42 572 580 10.1046/j.1537-2995.2002.00100.x 1:CAS:528: DC%2BD38Xlt1Kgs7w%3D 12084165
29. M Böhm C Betz W Miesbach M Krause C Auer H Geiger, et al. 2005 The course of ADAMTS13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine Br J Haem 129 644 652 10.1111/j.1365-2141.2005.05512.x (Pubitemid 40825826)
30. T Raife B Atkinson R Montgomery S Vesely K Friedman, et al. 2004 Severe deficiency of vWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients Transfusion 44 146 150 10.1111/j.1537-2995.2004.00626.x 1:CAS:528:DC%2BD2cXis1Wltrs%3D 14962303 (Pubitemid 38236374)
31. F Peyvandi S Lavoretano R Palla HB Feys K Vanhoorelbeke T Battaglioli, et al. 2008 ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission Haematology 93 232 239 10.3324/haematol.11739 1:CAS:528:DC%2BD1cXhsVSiu7zJ
32. S Ferrari F Scheiflinger M Rieger G Mudde M Wolf P Coppo, et al. 2007 Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity Blood 109 7 2815 2822 1:CAS:528:DC%2BD2sXjvVyns70%3D 17164349
33. P Coppo M Wolf A Veyradier S Bussel GA Malot C Millot, et al. 2005 Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura Br J Haem 132 66 74 10.1111/j.1365-2141. 2005.05837.x
34. E Bresin S Gastoldi E Daina D Belotti E Pogliani P Perseghin, et al. 2009 Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies Thromb Haemost 101 233 238 1:CAS:528:DC%2BD1MXjtVyrtLg%3D 19190804
35. GA Rock KH Shuman N Buskard VS Blanchette JG Kelton RC Nair, et al. 1991 Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura N Engl J Med 325 393 397 1:STN:280:DyaK3M3oslOnug%3D%3D 2062330
36. P Henon 1991 Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study Presse Med 20 1761 1767 1:STN:280:DyaK38%2Fptl2jtQ%3D%3D 1836595
37. EA Scott KE Puca BC Pietz BK Duchateau KD Friedman 2007 Comparison and stability of ADAMTS13 activity in therapeutic plasma products Transfusion 47 120 125 10.1111/j.1537-2995.2007.01074.x 1:CAS:528:DC%2BD2sXhsFajsLc%3D 17207240 (Pubitemid 46006319)
38. S Fontana JA Kremer Hovinga B Lämmle BM Taleghani 2006 Treatment of thrombotic thrombocytopenic purpura Vox Sang 90 245 254 10.1111/j.1423-0410. 2006.00747.x 1:CAS:528:DC%2BD28XmtlKisr4%3D 16635066
39. SN Hay JA Egan PA Millward N Bandarenko ME Brecher 2006 Patterns of platelet response in idiopathic TTP/HUS: frequency of declining platelet counts with plasma exchange and the recognition and significance of a pseudo refractory state Ther Apher Dial 10 3 237 41 10.1111/j.1744-9987.2006.00368.x 16817787 (Pubitemid 43979293)
40. JA Cohen ME Brecher N Bandarenko 1998 Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura J Clin Apher 13 16 19 10.1002/(SICI)1098-1101(1998)13:1<16::AID-JCA3>3.0. CO;2-C 1:STN:280:DyaK1c3ltVektg%3D%3D 9590492 (Pubitemid 28215135)
41. JA Egan SN Hay ME Brecher 2004 Frequency and significance of shistocytes in TTP/HUS patients at the discontinuation of plasma exchange therapy J Clin Apher 19 165 7 10.1002/jca.20017 15597353 (Pubitemid 40173968)
42. N Bandarenko Members of the US TTP Apheresis Study Group 1998 United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange J Clin Apher 13 133 41 10.1002/(SICI)1098-1101(1998)13: 3<133::AID-JCA7>3.0.CO;2-Z 1:STN:280:DyaK1M%2FktlOhtA%3D%3D 9828024 (Pubitemid 28507005)
43. M Rose A Eldor 1987 High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical Study of 38 subjects Am J Med 83 437 44 10.1016/0002-9343(87)90753-4 1:STN:280:DyaL1c%2FitFSlsA%3D%3D 3661582 (Pubitemid 18109902)
44. PT Onundarson JM Rowe JM Heal CW Francis 1992 Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura Ann Intern Med 152 791 6 10.1001/archinte.152.4.791 1:STN:280:DyaK383hsFSgsw%3D%3D
45. Nguyen L, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. Transfusion. 2009;49: 392-4 (Letters To The Editor).
46. WR Bell JJ Braine PM Ness TS Kickler 1991 Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients N Engl J Med 325 398 403 1:STN:280:DyaK3M3oslOnuw%3D%3D 2062331
47. A Ziman M Mitri E Klapper SH Pepkowitz D Goldfinger 2005 Combination vincristine and plasma exchange as initial therapy in subjects with thrombotic thrombocytopenic purpura: one institutions' experience and review of the literature Transfusion 45 41 9 10.1111/j.1537-2995.2005.03146.x 1:CAS:528:DC%2BD2MXht1Gqu7w%3D 15647017
48. JN George 2006 Thrombotic thrombocytopenic purpura N Engl J Med 354 1927 35 10.1056/NEJMcp053024 1:CAS:528:DC%2BD28XksVGiurk%3D 16672704 (Pubitemid 43872694)
49. F Ferrara C Copia M Annunziata A Spasiano C Di Grazia S Palmieri, et al. 1999 Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura Ann Hematol 78 521 3 10.1007/s002770050549 1:CAS:528:DyaK1MXntlaltr4%3D 10602896
50. MA Crowther N Heddle CP Hayward T Warkentin JG Kelton 1996 Splenectomy done during hematologic remission to prevent relapse in subjects with thrombotic thrombocytopenic purpura Ann Intern Med 125 294 6 1:STN:280: DyaK28zgtFWnsA%3D%3D 8678392
51. SR Cataland M Jin AK Ferketich, et al. 2006 An evaluation of cyclosporine and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura Br J Haematol 132 146 9
52. SR Cataland M Jin XL Zheng JN George HM Wu 2006 An evaluation of cyclosporine alone for the treatment of early recurrences of thrombotic thrombocytopenic purpura J Thromb Haemost 4 1162 4 10.1111/j.1538-7836.2006. 01909.x 1:STN:280:DC%2BD283msF2jtg%3D%3D 16689782
53. R Stasi A Pagano E Stipa S Amadori 2001 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 952 7 10.1182/blood.V98.4.952 1:CAS:528:DC%2BD3MXmtFeis70%3D 11493438
54. JCW Edwards L Szczepanski JD Szechinski A Filipowicz-Sosnowska P Emery DR Close, et al. 2004 Efficacy of B-cell-targeted therapy with rituximab in subjects with rheumatoid arthritis N Engl J Med 350 2572 81 10.1056/NEJMoa032534 1:CAS:528:DC%2BD2cXkvFKntrc%3D 15201414 (Pubitemid 38758544)
55. G Cartron H Watier J Golay P Solal-Celigny 2004 From the bench to the bedside: ways to improve rituximab efficacy Blood 104 9 2635 42 10.1182/blood-2004-03-1110 1:CAS:528:DC%2BD2cXpslKjs70%3D 15226177 (Pubitemid 39434941)
56. LA Gutterman B Kloster HM Tsai 2002 Rituximab therapy for refractory thrombotic thrombocytopenic purpura Blood Cells Mol Dis 28 385 91 10.1006/bcmd.2002.0522 12367582 (Pubitemid 35339342)
57. R Yomtovian W Niklinski B Silver R Sarode HM Tsai 2004 Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature Br J Haematol 124 787 95 10.1111/j.1365-2141.2004.04836.x 15009067 (Pubitemid 38365784)
58. PM Millward N Bandarenko PP Chang KF Stagg A Afenyi-Annan ME Brecher 2005 Cardiogenic shock complicates successful treatment of refractory TTP with rituximab Transfusion 45 9 1481 6 10.1111/j.1537-2995.2005.00560.x 1:STN:280:DC%2BD2Mvms1Snuw%3D%3D 16131381 (Pubitemid 44194652)
59. F Fakhouri JP Vernant A Veyradier M Wolf G Kaplanski R Binaut, et al. 2005 Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases Blood 106 1932 7 10.1182/blood-2005-03-0848 1:CAS:528:DC%2BD2MXhtVWksLzE 15933059 (Pubitemid 41291703)
60. HM Tsai K Shulman 2003 Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura Eur J Haematol 70 183 5 10.1034/j.1600-0609.2003.00026.x 12605663 (Pubitemid 36606079)
61. SR Foley K Webert DM Arnold GA Rock WF Clark D Barth, et al. 2009 A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura Kidney Int 75 Suppl 112 555 8
62. JN George RD Woodson JE Kiss K Kojouri SK Vesely 2006 Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the transfusion medicine/hemostasis clinical trials network with a systematic review of rituximab therapy for immune-mediated disorders J Clin Apher 21 49 56 10.1002/jca.20091 16619232
63. M Furlan R Robles M Galbursera G Remuzzi PA Kyrle B Brenner, et al. 1998 Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome N Eng J Med 339 22 1578 1584 10.1056/NEJM199811263392202 1:STN:280:DyaK1M%2Fjt1Sgsg%3D%3D (Pubitemid 28536132)
64. HM Tsai ECY Lian 1998 Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura N Eng J Med 339 22 1585 1594 10.1056/NEJM199811263392203 1:STN:280:DyaK1M%2Fjt1Sgsw%3D%3D (Pubitemid 28536133)
65. A Veyradier F Brivet M Wolf C Boyer-Neumann B Obert JP Girma, et al. 2001 Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome Hematol J 2 3 180 187 10.1038/sj.thj.6200093 11920243 (Pubitemid 32633669)
66. A Veyradier B Obert A Houllier D Meyer JP Girma, et al. 2001 Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome Blood 98 6 1765 1772 10.1182/blood.V98.6.1765 1:CAS:528:DC%2BD3MXntFWgsbY%3D 11535510
67. F Peyvandi S Ferrari S Lavoretano MT Canciani PM Mannucci, et al. 2004 von Willebrand factor cleaving protease (ADAMTS13) and ADAMTS13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura Br J Haematol 12 11 891 898
68. P Coppo D Bengoufa A Veyradier M Wolf A Bussel GA Millot, et al. 2004 Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement Medicine 83 4 233 244 10.1097/01.md.0000133622.03370.07 1:CAS:528:DC%2BD2cXltlOkurc%3D 15232311 (Pubitemid 38955446)
69. E Bobbio-Pallavincini L Gugliotta R Centurioni C Porta N Vianelli A Billio, et al. 1997 Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP Haematologica 82 4 429 435
70. ZR Zeigler RK Shadduck JF Gryn PB Rintels JN George EC Bessa, et al. 1997 Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP J Clin Apher 16 1 19 22 10.1002/jca.1003
71. G Rock, et al. 2005 The management of thrombotic thrombocytopenic purpura in 2005 Sem Thromb Hemostasis 31 6 709 716 10.1055/s-2005-925477 (Pubitemid 43063089)
72. PD Mintz A Neff M MacKenzie LT Goodnough C Hillyer C Kessler, et al. 2006 A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura Transfusion 46 10 1659 1662 10.1111/j.1537-2995.2006.00959.x (Pubitemid 44435721)